$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Medical drugs
Medical drugs
Medical drugs-Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Instructions for use and dosage of tilpotide/tilsiparatide (Mufenda) for weight loss and hypoglycemia
2026-02-01 22:25:32
Check Details
Analysis of the significance of skin rash with Pitobrutinib/Pitobrutinib (Zepali) targeted drugs
2026-02-01 22:25:32
Check Details
Talazoparib actual price reference table after medical insurance reimbursement
2026-02-01 22:25:32
Check Details
Summary of the effects, efficacy and clinical application of Crizotinib (Xalkori)
2026-02-01 22:25:32
Check Details
Whether aprocitentan is included in medical insurance and its reimbursement ratio and self-payment
2026-02-01 22:25:32
Check Details
Analysis of the target and physiological mechanism of action of tilpotide/tilsiparatide (Mufenda)
2026-02-01 22:25:32
Check Details
Analysis of whether the disease will relapse rapidly after discontinuation of Pitobrutinib/Pitobrutinib (Zepali)
2026-02-01 22:25:32
Check Details
Is the dosage form of Talazoparib (Tazena) capsules or other forms?
2026-02-01 22:25:32
Check Details
Crizotinib price and reference after medical insurance reimbursement in 2026
2026-02-01 22:25:32
Check Details
Mechanism and pharmacological analysis of aprocitentan in the treatment of pulmonary arterial hypertension
2026-02-01 22:25:32
Check Details
Clinical application effect of tilpotide/tilsiparatide (Mufenda) in the treatment of diabetes
2026-02-01 22:25:32
Check Details
Comprehensive explanation of the mechanism of action and clinical efficacy of Pitobrutinib/Pitobrutinib (Zepali)
2026-02-01 22:25:32
Check Details
1
2
...
2361
2362
2363
2364
2365
2366
2367
...
2440
2441
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
FDA Approves Zanidatamab (Ziihera): HER2 Bispecific Antibody Plus Immunotherapy for First-Line Gastric Cancer
2
Neurokinin Receptor Antagonists: A Non-Hormonal Approach to Menopausal Hot Flashes and Sleep Disturbances
3
FDA Approves Tauklarify for Tau PET Imaging in Alzheimer's Disease Assessment
4
First CELMoD Drug Zenbexus Wins FDA Accelerated Approval for Multiple Myeloma
5
FDA Approves First mRNA Flu Vaccine mFLUSIVA
6
FDA Approves Orzeyful, the World's First Orexin Receptor Agonist for Narcolepsy Type 1, Ushering in a New Era of Root-Cause Therapy
7
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
8
AbbVie’s TEPKINLY (epcoritamab) Plus R² Granted EU Approval for Relapsed/Refractory Follicular Lymphoma
9
Global Oncology Update: Breakthroughs in Advanced Cancer Survival and Novel Therapies
10
Phase 1 Study Progress of Ceralasertib in Combination with Durvalumab for Advanced NSCLC and HNSCC
11
Global Breakthroughs in Cancer Drugs and Advanced Treatment Technologies
12
ROS and Cancer: The Potential of Natural Antioxidants